医学
胰腺癌
吉西他滨
危险系数
胃肠病学
弹性成像
比例危险模型
旁侵犯
放射科
肿瘤科
癌症
内科学
病理
置信区间
超声波
作者
Si Shi,Chen Liang,Jin Xu,Qingcai Meng,Jie Hua,Xunan Yang,Quanxing Ni,Yu Lei
出处
期刊:Annals of Surgery
[Ovid Technologies (Wolters Kluwer)]
日期:2020-03-01
卷期号:271 (3): 559-565
被引量:29
标识
DOI:10.1097/sla.0000000000002998
摘要
Objective: The aim of this study was to investigate the association of the strain ratio (SR) with clinicopathologic features and the prognostic value of the SR in local pancreatic cancer. Background: The SR as obtained by endoscopic ultrasonography elastography is useful in the differential diagnosis of pancreatic diseases. However, its role in the prognostic prediction of pancreatic cancer remains unknown. Methods: A total of 78 resected pancreatic cancer patients and 93 locally advanced pancreatic cancer (LAPC) patients were enrolled in this study according to the inclusion criteria. Masson trichrome staining was used to evaluate the stromal proportion. Survival rates were calculated according to the Kaplan–Meier method and were compared using the log rank test. Multivariate analysis was performed with a Cox regression model. Results: The SR was positively associated with the stromal proportion of resected pancreatic cancer ( R = 0.768, P < 0.001). High SR was more likely in males ( P = 0.039) and was related to perineural invasion ( P = 0.022). High SR predicted unfavorable overall survival (OS) relative to low SR (15.4 vs. 25.8 mo, P = 0.017). SR was confirmed as an independent prognostic factor for resected pancreatic cancer based on multivariate analysis (hazard ratio = 1.939, P = 0.020). For LAPC patients who received nab-paclitaxel and gemcitabine, high SR was associated with improved prognosis (OS: 14.9 vs. 11.6 mo, P = 0.045), but this positive association was not observed in patients treated with other gemcitabine-based regimens (OS: 10.7 vs. 12.4 mo, P = 0.478). Conclusions: A high SR as obtained by endoscopic ultrasonography elastography was associated with poor prognosis of resected pancreatic cancer but predicted improved survival for LAPC patients treated with the nab-paclitaxel and gemcitabine regimen.
科研通智能强力驱动
Strongly Powered by AbleSci AI